Viking Therapeutics Inc. (NASDAQ: VKTX) announced the publication of results from its Phase 2 VENTURE trial of VK2735 in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE